Track Daiichi Sankyo Company, Limited — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Daiichi Sankyo Company, Limited DSNKY · Stock Open Daiichi Sankyo Company, Limited in new tab

17.89 USD
P/E
20.84
EPS
0.86
Yield
3.13%
Safety Score
42
P/B
3.04
ROE
14.81
Target Price
23.35 USD
Loading chart...
Key Metrics
Earnings dateOct. 30, 2026
P/E20.84
EPS0.86
Book Value5.90
Price to Book3.04
Debt/Equity29.39
Growth
Revenue Growth0.21%
Earnings Growth-0.18%
Estimates
Target Mean Price23.35
Dividend
Dividend Yield3.13%
Annual dividends89.00 USD
Ex-Div. DateSept. 30, 2026
Payout59.07%
5y avg Yield1.30%

DCF valuation

Model fair value for Daiichi Sankyo Company, Limited (DSNKY)
Result
Sign in to run the valuation for DSNKY.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
2 analysts · consensus Strong buy · mean target 23.35 USD (low 22.00, high 24.70) · as of 21 Oct 2026
Low 22.00
Mean 23.35
High 24.70
Price 17.89
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Daiichi Sankyo Company, Limited Logo Daiichi Sankyo Company, Limited Analysis (DSNKY)

Japan Health Care Official Website Stock

Is Daiichi Sankyo Company, Limited a good investment? Daiichi Sankyo Company, Limited (DSNKY) is currently trading at 17.89 USD. Market analysts have a consensus price target of 23.35 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 20.84. This valuation is generally in line with the broader market.

Earnings Schedule: Daiichi Sankyo Company, Limited is expected to release its next earnings report on Oct. 30, 2026.

For income investors, Daiichi Sankyo Company, Limited pays a dividend yield of 3.13%. With a payout ratio of 59%, the dividend appears sustainable.

Investor FAQ

Does Daiichi Sankyo Company, Limited pay a dividend?

Yes, it pays an annual dividend of 89.00 USD (3.13% yield).

What asset class is Daiichi Sankyo Company, Limited?

Daiichi Sankyo Company, Limited is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Oct. 30, 2026. The company currently has a trailing EPS of 0.86.

Company Profile

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan and internationally. The company offers Enhertu for the treatment of HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule for colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3, as well as symptomatic TGCT; Vanflyta, a FLT3 inhibitor for the treatment of acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency; and Datroway for the treatment of HR positive and HER2 negative breast cancer, as well as NSCLC. It also provides Lixiana and Savaysa, which are direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT, which are antihypertensive agents; Nilemdo that lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe that reduces cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgality for the treatment of migraine attacks; Pralia for the treatment of osteoporosis and bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications and GCTB; Tarlige for the treatment of neuropathic pain; Venofer for the treatment of iron deficiency anemia; Vimpat, an anti-seizure medication; and Reyvow for the treatment of acute migraine attacks. Further, it provides Daichirona, a coronavirus RNA vaccine; Flumist, an intranasal live attenuated influenza vaccine; adsorbed cell culture-derived influenza vaccine; measles rubella combined vaccine; and mump vaccine. The company was formerly known as Sankyo Co. Ltd. and changed its name to Daiichi Sankyo Company, Limited in September 2005. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Chuo, Japan.

Exchange Ticker
PNK (United States) DSNKY
Trades
Dividend Yield
3.13%
5y avg 1.30%
Annual Dividends
89.00USD
Next Ex. Div Date
Sept. 30, 2026
Payout Ratio
59.07%
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2027
0.44 USD
June 23, 2027 (estimated) 0.4378
▸2026
0.56 USD
Dec. 10, 2026 0.3149
June 23, 2026 0.2444
▸2025
0.46 USD
Dec. 17, 2025 0.2496
July 1, 2025 0.2070
▸2024
0.39 USD
Dec. 17, 2024 0.1970
June 25, 2024 0.1901
▸2023
0.24 USD
Dec. 15, 2023 0.1383
June 27, 2023 0.1061
▸2022
0.21 USD
Dec. 8, 2022 0.1104
July 5, 2022 0.0991
▸2021
0.24 USD
Dec. 9, 2021 0.1194
June 29, 2021 0.1221
▸2020
0.72 USD
Dec. 8, 2020 0.3880
June 23, 2020 0.3285
▸2019
0.64 USD
Dec. 10, 2019 0.3225
June 26, 2019 0.3224
▸2018
0.63 USD
Dec. 10, 2018 0.3082
June 26, 2018 0.3188
▸2017
0.63 USD
Dec. 8, 2017 0.3124
June 27, 2017 0.3137
▸2016
0.59 USD
Dec. 8, 2016 0.3063
June 30, 2016 0.2871
▸2015
0.57 USD
Dec. 8, 2015 0.3247
July 10, 2015 0.2417
▸2014
0.55 USD
Dec. 15, 2014 0.2538
July 1, 2014 0.2943
▸2013
0.60 USD
Dec. 9, 2013 0.2915
July 1, 2013 0.3071
▸2012
3.17 USD
Dec. 10, 2012 1.3733
July 2, 2012 1.4221
July 2, 2012 0.3772
▸2011
0.76 USD
Dec. 15, 2011 0.3857
July 13, 2011 0.3693
▸2010
0.69 USD
Dec. 15, 2010 0.3555
July 14, 2010 0.3357
▸2009
0.76 USD
Dec. 15, 2009 0.3442
July 14, 2009 0.4161
Upcoming Dividends
Name Payment Date Status Amount
Daiichi Sankyo Company, Limited Dec 10, 2026 Upcoming 0.31492 USD
Daiichi Sankyo Company, Limited Jun 23, 2026 0.24439 USD
Stock Splits
Split Date Split Ratio to 1
Oct. 9, 2020 3:1
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion